Literature DB >> 12469459

Preoperative evaluation of primary hyperparathyroidism: role of diagnostic imaging.

Giuseppe Panzironi1, Laura Falvo, Marina De Vargas Macciucca, Antonio Catania, Salvatore Sorrenti, Alessia Biancafarina, Flaminia De Cristofaro, Francesca Ricci, Enrico De Antoni.   

Abstract

This study analyses the diagnostic value of preoperative diagnostic imaging examinations in the identification and location of pathological parathyroid glands. We examined 77 patients with primary hyperparathyroidism using ultrasonography of the neck and Tc99m-MIBI scintigraphy for preoperative assessment purposes. All patients underwent surgical treatment. We compared the diagnostic imaging results with those furnished by histological examinations. TC99m-MIBI scintigraphy revealed the presence of a pathological parathyroid gland in 74/77 cases (96.1%) compared with 75/77 cases (97.4%) diagnosed by ultrasonography. The two examinations combined detected pathological glands in 100% of cases. The location of the pathological gland was correct in 57 cases (74.0%) at scintigraphy and in 56 cases (72.7%) at ultrasonography. In one case (1.3%) persistent hyperparathyroidism was demonstrated. There were no cases of relapse. In this study preoperative evaluation by ultrasonography and scintigraphy displayed great sensitivity in identifying and locating pathological parathyroid glands. Surgical neck exploration is still the gold standard in the correct location of pathological parathyroid glands measuring less than 5 mm.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12469459

Source DB:  PubMed          Journal:  Chir Ital        ISSN: 0009-4773


  2 in total

1.  Pathological fracture: an ill telltale in osteoporosis.

Authors:  Ihsan Ustün; Levent Ozçakar; Metin Seker; Nilgün Ustün; Selma Karaahmetoğlu
Journal:  Rheumatol Int       Date:  2003-09-10       Impact factor: 2.631

Review 2.  How to localize parathyroid tumors in primary hyperparathyroidism?

Authors:  T Uruno; E Kebebew
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.